DEXMEDETOMIDINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dexmedetomidine hydrochloride and what is the scope of freedom to operate?
Dexmedetomidine hydrochloride
is the generic ingredient in three branded drugs marketed by Bioxcel, Accord Hlthcare, Actavis Inc, Am Regent, Amneal, Amneal Pharms Co, Baxter Hlthcare Corp, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hikma, Meitheal, Milla Pharms, Mylan Institutional, Mylan Labs Ltd, Piramal Critical, Rising, Sandoz, Tagi, Teva Pharms Usa, Wilshire Pharms Inc, Zydus Pharms, Hospira, Hq Spclt Pharma, and Somerset, and is included in thirty-two NDAs. There are twenty patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Dexmedetomidine hydrochloride has one hundred and twenty-three patent family members in thirty-seven countries.
There are nine drug master file entries for dexmedetomidine hydrochloride. Twenty-nine suppliers are listed for this compound.
Summary for DEXMEDETOMIDINE HYDROCHLORIDE
International Patents: | 123 |
US Patents: | 20 |
Tradenames: | 3 |
Applicants: | 28 |
NDAs: | 32 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 29 |
Raw Ingredient (Bulk) Api Vendors: | 97 |
Clinical Trials: | 1,344 |
Patent Applications: | 344 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DEXMEDETOMIDINE HYDROCHLORIDE |
What excipients (inactive ingredients) are in DEXMEDETOMIDINE HYDROCHLORIDE? | DEXMEDETOMIDINE HYDROCHLORIDE excipients list |
DailyMed Link: | DEXMEDETOMIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DEXMEDETOMIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Alabama at Birmingham | Phase 1 |
Boston Medical Center | Phase 4 |
Children's Mercy Hospital Kansas City | Phase 4 |
Pharmacology for DEXMEDETOMIDINE HYDROCHLORIDE
Drug Class | Central alpha-2 Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha2-Agonists |
Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for DEXMEDETOMIDINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DEXMEDETOMIDINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for DEXMEDETOMIDINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PRECEDEX | Injection | dexmedetomidine hydrochloride | 4 mcg/mL, 20 mL vials | 021038 | 1 | 2015-09-30 |
PRECEDEX | Injection | dexmedetomidine hydrochloride | 4 mcg/mL, 50 mL and 100 mL vials | 021038 | 1 | 2013-12-26 |
PRECEDEX | Injection | dexmedetomidine hydrochloride | 100 mcg/mL | 021038 | 1 | 2009-04-08 |
US Patents and Regulatory Information for DEXMEDETOMIDINE HYDROCHLORIDE
Expired US Patents for DEXMEDETOMIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-004 | Nov 14, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DEXMEDETOMIDINE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Taiwan | 201332546 | Dexmedetomidine premix formulation | ⤷ Sign Up |
Canada | 3145388 | REGIMES DE TRAITEMENT NON SEDATIFS A BASE DE DEXMEDETOMIDINE (NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS) | ⤷ Sign Up |
Japan | 7008153 | ⤷ Sign Up | |
South Africa | 202006636 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | ⤷ Sign Up |
China | 114375191 | 非镇静的右美托咪定治疗方案 (Non-sedative dexmedetomidine treatment regimen) | ⤷ Sign Up |
China | 107802624 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DEXMEDETOMIDINE HYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0300652 | 2003C/005 | Belgium | ⤷ Sign Up | PRODUCT NAME: CHLORHYDRATE DE DEXMEDETOMIDINE; REGISTRATION NO/DATE: EU/2/02/033/001 20020903 |
0300652 | C300117 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.